Business
Kiora Pharmaceuticals Reports 2022 Financial Results; Provides Update on Clinical Development Progress
Encinitas, California--(Newsfile Corp. - March 23, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today is providing a
About this update from Kiora Pharmaceuticals, Inc.
[{"type":"text","content":"Encinitas, California--(Newsfile Corp. - March 23, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (\"Kiora\" or the \"Company\") today is providing a business update and reporting financial results for the year ended December 31, 2022.\nCEO Commentary:\n\"In 2022, we advanced our pipeline of three differentiated assets across rare, orphan and underserved eye disease indications,\" said Brian M. Strem, Ph.D., President and Chief Executive Officer of Kiora. \"Enrollment is ongoing in our Phase 1b study of KIO-301 in patients with Retinitis Pigmentosa (RP); we initiated a Phase 2 study of KIO-101 in patients whose autoimmune disease manifests on the ocular surface; and we recently completed a Phase 2 study of KIO-201 in patients suffering from Persistent Corneal Epithelial Defects (PCEDs).\n\"KIO-301, our flagship asset, is targeting a tremendous need in patients with RP, namely vision restoration. Unfortunately, there are no approved therapies to help patients who have this orphan disease, and based on this as well as our operational efficiencies, we are able to pursue an accelerated clinical development path for this program. Our phase 1b trial (termed \"ABACUS\") began dosing patients late last year. Enrollment is on track to enable full trial results expected before the end of 2023. In addition to safety, tolerability and visual efficacy assessments, we are incorporating novel and rigorous imaging and analysis protocols to ensure the trial is as informative as possible. This includes the use of functional MRI to assess visual activity in the brain. As a confirmatory measure, and being an open label study, we reviewed preliminary observations from the first two patients treated. Thus far, there have been no reported adverse events, including ocular adverse events, and patient-reported outcomes indicate an improvement in the ability to perceive light, delineate contrast between light and dark and improvement in overall vision function following KIO-301 injection. Based on these observations and more, we are continuing enrollment and look forward to reporting additional early results on April 27, 2023, at the Association for Research in Vision and Ophthalmology (ARVO) annual conference in New Orleans. Beyond development of KIO-301 as a potential vision restoring treatment for RP, we are exploring this small molecule 'photoswi...